New Step by Step Map For P-gb-IN-1
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage various intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Key demo aims ended up To judge the security and tolerability of sifalimumab in dermatomyositis or polymyositis people,